NASDAQ:BCYC Bicycle Therapeutics (BCYC) Stock Price, News & Analysis $4.74 +0.02 (+0.42%) Closing price 05/13/2026 04:00 PM EasternExtended Trading$4.83 +0.09 (+1.88%) As of 04:05 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Bicycle Therapeutics Stock (NASDAQ:BCYC) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Bicycle Therapeutics alerts:Sign Up Key Stats Today's Range$4.65▼$4.7850-Day Range$4.31▼$5.6352-Week Range$4.24▼$9.36Volume250,055 shsAverage Volume391,989 shsMarket Capitalization$330.43 millionP/E RatioN/ADividend YieldN/APrice Target$14.00Consensus RatingHold Company Overview Bicycle Therapeutics plc is a clinical-stage biotechnology company specializing in the discovery and development of novel peptide therapeutics based on its proprietary bicyclic peptide platform. The company’s core technology leverages constrained peptide structures that combine the binding specificity of biologics with the favorable tissue-penetration properties of small molecules. This approach is designed to generate highly selective drug candidates with potential applications across a range of therapeutic areas, including oncology, neuroscience and immunology. Bicycle Therapeutics maintains a diversified pipeline of internally developed programs as well as collaborations with leading pharmaceutical partners. Its oncology portfolio includes targeted agents aimed at tumor-associated receptors and tumor-penetrating ligands designed to deliver therapeutic payloads. In parallel, the company is advancing candidates in neuroscience and immuno-oncology, seeking to address high-unmet-need conditions. Bicycle’s programs are being evaluated in preclinical and early clinical studies, and the company has established research collaborations with several global biopharmaceutical organizations to accelerate the clinical development of its lead molecules. Headquartered in Cambridge, UK, Bicycle Therapeutics has expanded its presence with operations in the United States to support its growing clinical activities and partnerships. The company is led by an experienced management team with deep expertise in peptide chemistry, translational research and drug development. By integrating its proprietary platform with strategic alliances, Bicycle Therapeutics aims to advance a new class of precision medicines capable of reaching challenging therapeutic targets with improved safety and efficacy profiles.AI Generated. May Contain Errors. Read More Bicycle Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks71st Percentile Overall ScoreBCYC MarketRank™: Bicycle Therapeutics scored higher than 71% of companies evaluated by MarketBeat, and ranked 237th out of 864 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.2 / 5Analyst RatingHold Consensus RatingBicycle Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.44, and is based on no strong buy ratings, 5 buy ratings, 3 hold ratings, and 1 sell rating.Upside PotentialBicycle Therapeutics has a consensus price target of $14.00, representing about 195.4% upside from its current price of $4.74.Amount of Analyst CoverageBicycle Therapeutics has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Bicycle Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Bicycle Therapeutics are expected to decrease in the coming year, from ($1.99) to ($2.07) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Bicycle Therapeutics is -1.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Bicycle Therapeutics is -1.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBicycle Therapeutics has a P/B Ratio of 0.60. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted4.59% of the float of Bicycle Therapeutics has been sold short.Short Interest Ratio / Days to CoverBicycle Therapeutics has a short interest ratio ("days to cover") of 7.88.Change versus previous monthShort interest in Bicycle Therapeutics has recently increased by 11.05%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldBicycle Therapeutics does not currently pay a dividend.Dividend GrowthBicycle Therapeutics does not have a long track record of dividend growth. News and Social Media3.4 / 5News Sentiment1.41 News SentimentBicycle Therapeutics has a news sentiment score of 1.41. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Bicycle Therapeutics this week, compared to 3 articles on an average week.Search InterestOnly 1 people have searched for BCYC on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat Follows1 people have added Bicycle Therapeutics to their MarketBeat watchlist in the last 30 days. Company Ownership2.1 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Bicycle Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $49,363.00 in company stock.Percentage Held by Insiders22.90% of the stock of Bicycle Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions86.15% of the stock of Bicycle Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Bicycle Therapeutics' insider trading history. Receive BCYC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Bicycle Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. BCYC Stock News HeadlinesBicycle Therapeutics (NASDAQ:BCYC) Cut to Strong Sell at Wall Street ZenMay 10, 2026 | americanbankingnews.comBicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) Receives Average Recommendation of "Hold" from BrokeragesMay 5, 2026 | americanbankingnews.comIran War Update: Trump’s Hand-Written Letter Reveals What Comes NextJim Rickards has uncovered what he believes is Trump's economic plan, with a key trigger date of May 15. The Financial Times estimates this move could help unleash $100 trillion in new wealth. Billionaire investors John Paulson, Ray Dalio, and Paul Tudor Jones are already said to be preparing. The window to get ahead of this may be closing. | Paradigm Press (Ad)Bicycle Therapeutics Provides Update on Nuzefatide Pevedotin and EphA2 Pipeline at the AACR Annual Meeting 2026April 20, 2026 | businesswire.comRBC Capital lowers its price target on Bicycle Therapeutics plc (BCYC) to $7 from $11April 4, 2026 | msn.comBicycle Therapeutics Plc Sponsored ADRApril 3, 2026 | cnn.comBicycle Therapeutics plc - Depositary Receipt (BCYC) price target decreased by 29.27% to 13.17March 28, 2026 | msn.com12 Best Get Rich Quick Stocks to Buy According to Hedge FundsMarch 14, 2026 | msn.comSee More Headlines BCYC Stock Analysis - Frequently Asked Questions How have BCYC shares performed this year? Bicycle Therapeutics' stock was trading at $7.08 at the beginning of 2026. Since then, BCYC shares have decreased by 33.1% and is now trading at $4.74. How were Bicycle Therapeutics' earnings last quarter? Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) issued its quarterly earnings results on Thursday, April, 30th. The company reported ($0.87) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.62) by $0.25. The firm earned $0.89 million during the quarter, compared to analysts' expectations of $7.50 million. Bicycle Therapeutics had a negative trailing twelve-month return on equity of 35.74% and a negative net margin of 344.95%. When did Bicycle Therapeutics IPO? Bicycle Therapeutics (BCYC) raised $65 million in an IPO on Thursday, May 23rd 2019. The company issued 4,333,333 shares at $14.00-$16.00 per share. Goldman Sachs, Jefferies and Piper Jaffray acted as the underwriters for the IPO and Canaccord Genuity was co-manager. Who are Bicycle Therapeutics' major shareholders? Top institutional shareholders of Bicycle Therapeutics include Principal Financial Group Inc. (1.69%), Sei Investments Co. (0.08%) and R Squared Ltd (0.03%). Insiders that own company stock include Bros Advisors Lp Baker, Kevin Lee, Alistair Milnes, Michael Skynner, Jennifer Scott Perry, Alethia Young, Santiago Arroyo, Travis Alvin Thompson, Nicholas Keen, Michael Charles Ferguso Hannay, Nigel Crockett and Robert Charles Swanton. View institutional ownership trends. How do I buy shares of Bicycle Therapeutics? Shares of BCYC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Bicycle Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Bicycle Therapeutics investors own include Vale (VALE), uniQure (QURE), Clean Energy Fuels (CLNE), Paycom Software (PAYC), Curaleaf (CURLF) and Company Calendar Last Earnings4/30/2026Today5/13/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (49m+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 BCYC's financial health is in the Red zone, according to TradeSmith. BCYC has been in this zone for over 49 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:BCYC CIK1761612 Webwww.bicycletherapeutics.com Phone441223261503FaxN/AEmployees240Year Founded2009Price Target and Rating Average Price Target for Bicycle Therapeutics$14.00 High Price Target$36.00 Low Price Target$7.00 Potential Upside/Downside+195.4%Consensus RatingHold Rating Score (0-4)2.44 Research Coverage9 Analysts Profitability EPS (Trailing Twelve Months)($3.15) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$218.96 million Net Margins-344.95% Pretax Margin-342.73% Return on Equity-35.74% Return on Assets-29.54% Debt Debt-to-Equity RatioN/A Current Ratio12.66 Quick Ratio12.66 Sales & Book Value Annual Sales$72.86 million Price / Sales4.54 Cash FlowN/A Price / Cash FlowN/A Book Value$7.95 per share Price / Book0.60Miscellaneous Outstanding Shares69,710,000Free Float53,744,000Market Cap$330.43 million OptionableOptionable Beta1.56 Social Links 7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (NASDAQ:BCYC) was last updated on 5/14/2026 by MarketBeat.com Staff. From Our PartnersIs this AI lab Elon’s SpaceX lifeline?Elon Musk went from calling one AI lab 'evil' to striking a deal giving it access to SpaceX's entire Colossus ...Chaikin Analytics | SponsoredThe one number Musk can't hide in the S-1When SpaceX files its S-1 in June, one number will stand out - power consumption. Running 1 million GPUs requi...Behind the Markets | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...American Alternative | SponsoredCollect $1,170 a month from silverI've Rarely Seen This With Silver This combination - 20% dividends + 68% share appreciation - never happens...Investors Alley | SponsoredThe system holding the dollar together is gone…Saudi Arabia has terminated its 1974 petrodollar agreement with the United States - the deal that forced every...Golden Portfolio | SponsoredSpaceX IPO Warning: Before you buy any SpaceX shares, read this.The SpaceX IPO is valued at $1.75 trillion - but buying shares directly may not be the strongest play availabl...Weiss Ratings | SponsoredThis is the worst news for stocks in 50 yearsGoldman Sachs and Morgan Stanley are issuing a rare warning: what's ahead for U.S. stocks could be the worst e...TradeSmith | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bicycle Therapeutics PLC Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Bicycle Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
